Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | T3011 |
Synonyms | |
Therapy Description |
T3011 is an oncolytic herpes simplex virus-1 (HSV-1), engineered to express the cytokine IL-12 and an antibody against PD-1, which may block the immune checkpoint, and lead to inhibition of tumor cell proliferation (NCI Drug Dictionary) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
T3011 | T 3011|T-3011 | T3011 is an oncolytic herpes simplex virus-1 (HSV-1), engineered to express the cytokine IL-12 and an antibody against PD-1, which may block the immune checkpoint, and lead to inhibition of tumor cell proliferation (NCI Drug Dictionary) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04370587 | Phase I | T3011 | A Clinical Study of T3011 in Patients With Advanced Cutaneous or Subcutaneous Malignancies | Recruiting | USA | AUS | 0 |
NCT04780217 | Phase Ib/II | T3011 Pembrolizumab + T3011 | A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |